Covariate Adjustment Sharply Improves Clinical Trial Precision
MONT-SAINT-GUIBERT, Belgium, September 4, 2025 — A recent peer-reviewed study in The Journal of Pain demonstrates that a streamlined...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
MONT-SAINT-GUIBERT, Belgium, September 4, 2025 — A recent peer-reviewed study in The Journal of Pain demonstrates that a streamlined...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...
CARLSBAD, Calif., August 21, 2025 — The U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen), the first...
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...
FORT LAUDERDALE, September 3, 2025 – As daylight dwindles in parts of the northern hemisphere, maintaining adequate vitamin D...
Andelyn Biosciences, a leading cell and gene therapy CDMO, has partnered with Tern Therapeutics to perform late-stage Process Performance...
AliveDx, a global in-vitro diagnostics innovator, today announced it has submitted a 510(k) premarket notification to the U.S. Food...
PHILADELPHIA, September 3, 2025 — The first patient has been dosed in a clinical trial evaluating Synecta™ T1 cell-derived...
NEW YORK, September 3, 2025 — Spring Health has officially joined the Workday Wellness Partner Program as a Strategic...
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
